Glioblastoma multiforme (GBM)
Conditions
Brief summary
OS defined as the time from randomization until death.
Detailed description
PFS, defined as the length of time from randomization to disease progression based on MRI scan or death, whichever occurs first., EFS, defined as the length of time from randomization to disease progression, death, or discontinuation of treatment for any reason (e.g., toxicity, intolerance, disease-related conditions, or failure to respond), ORR, defined as CR + PR per RANO criteria, DCR, defined as CR + PR + SD per RANO criteria; SD is defined as lack of progression of disease based on MRI scan obtained at least (CCI) weeks after initiation of therapy
Interventions
DRUGCecenu® 40 mg Kapsel
Sponsors
Cns Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS defined as the time from randomization until death. | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS, defined as the length of time from randomization to disease progression based on MRI scan or death, whichever occurs first., EFS, defined as the length of time from randomization to disease progression, death, or discontinuation of treatment for any reason (e.g., toxicity, intolerance, disease-related conditions, or failure to respond), ORR, defined as CR + PR per RANO criteria, DCR, defined as CR + PR + SD per RANO criteria; SD is defined as lack of progression of disease based on MRI scan obtained at least (CCI) weeks after initiation of therapy | — |
Countries
France, Italy, Spain
Outcome results
None listed